Agency Information Collection Activities: Submission to OMB for Review and Approval; Public Comment Request; Maternal, Infant, and Early Childhood Home Visiting Program Home Visiting Program Budget Assistance Tool, 12951-12953 [2023-04185]
Download as PDF
<![CDATA[
Federal Register / Vol. 88, No. 40 / Wednesday, March 1, 2023 / Notices
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with § 10.20 (21
CFR 10.20) and other applicable
disclosure law. For more information
about FDA’s posting of comments to
public dockets, see 80 FR 56469,
September 18, 2015, or access the
information at: https://
www.govinfo.gov/content/pkg/FR-201509-18/pdf/2015-23389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852, 240–402–7500.
FOR FURTHER INFORMATION CONTACT:
Beverly Friedman, Office of Regulatory
Policy, Food and Drug Administration,
10903 New Hampshire Ave., Bldg. 51,
Rm. 6250, Silver Spring, MD 20993,
301–796–3600.
SUPPLEMENTARY INFORMATION:
ddrumheller on DSK120RN23PROD with NOTICES
I. Background
The Drug Price Competition and
Patent Term Restoration Act of 1984
(Pub. L. 98–417) and the Generic
Animal Drug and Patent Term
Restoration Act (Pub. L. 100–670)
generally provide that a patent may be
extended for a period of up to 5 years
so long as the patented item (human
drug or biologic product, animal drug
product, medical device, food additive,
or color additive) was subject to
regulatory review by FDA before the
item was marketed. Under these acts, a
product’s regulatory review period
forms the basis for determining the
amount of extension an applicant may
receive.
A regulatory review period consists of
two periods of time: a testing phase and
an approval phase. For human drug
products, the testing phase begins when
the exemption to permit the clinical
investigations of the drug becomes
effective and runs until the approval
phase begins. The approval phase starts
with the initial submission of an
application to market the human drug
product and continues until FDA grants
permission to market the drug product.
Although only a portion of a regulatory
review period may count toward the
VerDate Sep<11>2014
18:10 Feb 28, 2023
Jkt 259001
actual amount of extension that the
Director of USPTO may award (for
example, half the testing phase must be
subtracted as well as any time that may
have occurred before the patent was
issued), FDA’s determination of the
length of a regulatory review period for
a human drug product will include all
of the testing phase and approval phase
as specified in 35 U.S.C. 156(g)(1)(B).
FDA has approved for marketing the
human drug product, VYZULTA
(latanoprostene bunod). VYZULTA is
indicated for reduction of intraocular
pressure in patients with open-angle
glaucoma or ocular hypertension.
Subsequent to this approval, the USPTO
received patent term restoration
applications for VYZULTA (U.S. Patent
Nos. 7,273,946; 7,629,345; and
8,058,467) from Nicox S.A., and the
USPTO requested FDA’s assistance in
determining the patents’ eligibility for
patent term restoration. In a letter dated
May 13, 2019, FDA advised the USPTO
that this human drug product had
undergone a regulatory review period
and that the approval of VYZULTA
represented the first permitted
commercial marketing or use of the
product. Thereafter, the USPTO
requested that FDA determine the
product’s regulatory review period.
II. Determination of Regulatory Review
Period
FDA has determined that the
applicable regulatory review period for
VYZULTA is 3,879 days. Of this time,
3,043 days occurred during the testing
phase of the regulatory review period,
while 836 days occurred during the
approval phase. These periods of time
were derived from the following dates:
1. The date an exemption under
section 505(i) of the Federal Food, Drug,
and Cosmetic Act (FD&C Act) (21 U.S.C.
355(i)) became effective: March 23,
2007. FDA has verified the applicant’s
claim that the date the investigational
new drug application became effective
was on March 23, 2007.
2. The date the application was
initially submitted with respect to the
human drug product under section 505
of the FD&C Act: July 21, 2015. FDA has
verified the applicant’s claim that the
new drug application (NDA) for
VYZULTA (NDA 207795) was initially
submitted on July 21, 2015.
3. The date the application was
approved: November 2, 2017. FDA has
verified the applicant’s claim that NDA
207795 was approved on November 2,
2017.
This determination of the regulatory
review period establishes the maximum
potential length of a patent extension.
However, the USPTO applies several
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
12951
statutory limitations in its calculations
of the actual period for patent extension.
In its applications for patent extension,
this applicant seeks 1,826 days or 1,507
days of patent term extension.
III. Petitions
Anyone with knowledge that any of
the dates as published are incorrect may
submit either electronic or written
comments and, under 21 CFR 60.24, ask
for a redetermination (see DATES).
Furthermore, as specified in § 60.30 (21
CFR 60.30), any interested person may
petition FDA for a determination
regarding whether the applicant for
extension acted with due diligence
during the regulatory review period. To
meet its burden, the petition must
comply with all the requirements of
§ 60.30, including but not limited to:
must be timely (see DATES), must be
filed in accordance with § 10.20, must
contain sufficient facts to merit an FDA
investigation, and must certify that a
true and complete copy of the petition
has been served upon the patent
applicant. (See H. Rept. 857, part 1, 98th
Cong., 2d sess., pp. 41–42, 1984.)
Petitions should be in the format
specified in 21 CFR 10.30.
Submit petitions electronically to
https://www.regulations.gov at Docket
No. FDA–2013–S–0610. Submit written
petitions (two copies are required) to the
Dockets Management Staff (HFA–305),
Food and Drug Administration, 5630
Fishers Lane, Rm. 1061, Rockville, MD
20852.
Dated: February 24, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023–04178 Filed 2–28–23; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Agency Information Collection
Activities: Submission to OMB for
Review and Approval; Public Comment
Request; Maternal, Infant, and Early
Childhood Home Visiting Program
Home Visiting Program Budget
Assistance Tool
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services.
ACTION: Notice.
AGENCY:
In compliance with the
Paperwork Reduction Act of 1995,
HRSA submitted an Information
Collection Request (ICR) to the Office of
SUMMARY:
E:\FR\FM\01MRN1.SGM
01MRN1
ddrumheller on DSK120RN23PROD with NOTICES
12952
Federal Register / Vol. 88, No. 40 / Wednesday, March 1, 2023 / Notices
Management and Budget (OMB) for
review and approval. Comments
submitted during the first public review
of this ICR will be provided to OMB.
OMB will accept further comments from
the public during the review and
approval period. OMB may act on
HRSA’s ICR only after the 30-day
comment period for this notice has
closed.
DATES: Comments on this ICR should be
received no later than March 31, 2023.
ADDRESSES: Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under Review—Open for
Public Comments,’’ or by using the
search function.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the data collection plans and draft
instruments, email paperwork@hrsa.gov
or call Samantha Miller, the acting
HRSA Information Collection Clearance
Officer, at 301–594–4394.
SUPPLEMENTARY INFORMATION:
Information Collection Request Title:
Maternal, Infant, and Early Childhood
Home Visiting (MIECHV) Program
Home Visiting Budget Assistance Tool
(HV–BAT), OMB No. 0906–0025—
Revision.
Abstract: HRSA is requesting an
extension of approval and revision to
the burden estimates for the HV–BAT.
The tool collects information on
standardized cost metrics from
programs that deliver home visiting
services. Entities receiving MIECHV
formula funds that are states,
jurisdictions, and nonprofit awardees
are required to submit cost data using
the HV–BAT to HRSA once every 3
years to be reviewed for accuracy and
quality control and to collect data to
estimate national program costs.
The MIECHV Program, authorized by
section 511 of the Social Security Act,
42 U.S.C. 711, and administered by
HRSA in partnership with the
Administration for Children and
Families, supports voluntary, evidencebased home visiting services during
pregnancy and for parents with young
children up to kindergarten entry.
States, tribal entities, and certain
nonprofit organizations are eligible to
receive funding from the MIECHV
Program and have the flexibility to tailor
the program to serve the specific needs
of their communities. Funding
recipients may subaward grant funds to
local implementing agencies (LIAs) to
VerDate Sep<11>2014
18:10 Feb 28, 2023
Jkt 259001
provide services to eligible families in
at-risk communities. HRSA is making
the following changes to the HV–BAT:
• Updating the burden estimate for
completing the HV–BAT based on
recently gathered information. The
burden estimate reflects both awardee
and LIA staff hours to complete an HV–
BAT. HRSA expects the majority of
awardees will be submitting data from
multiple LIAs, and some LIAs may
submit multiple HV–BATs to account
for each model implemented at their
site.
• Translating the HV–BAT data
collection instrument into Spanish to
expand accessibility.
A 60-day notice was published in the
Federal Register on November 8, 2022,
87 FR 67481–82. HRSA received five
responses to the request for public
comment. Two commentors are current
MIECHV awardees, one is a home
visiting model developer, one is a
national membership organization
representing MIECHV awardees, and
one is a consultancy group directing a
national initiative relating to home
visiting. Commentors posed questions
about the utility of HV–BAT data (e.g.,
relevance of data collected from the
prior year, lack of data context collected
through the tool, how HRSA will
account for variation in local labor
markets) and of the specific data items
collected (e.g., necessity of collecting
rural and frontier visit data, MIECHV
funding percentages, and combined
salary and fringe data). In addition,
commentors provided recommendations
for updating burden estimates and
improving HRSA’s technical assistance
and feedback (e.g., providing support for
estimating in-kind costs and additional
suggestions for review and feedback
from HRSA).
HRSA views HV–BAT as an important
tool for collecting standardized cost
information across awardees,
understanding the comprehensive costs
of home visiting, and informing program
planning and policy. During HV–BAT
tool development, HRSA reviewed
available cost measurement reports,
tested the tool with awardees during the
pilot and feasibility studies, and
assessed the types of data that would be
critical for understanding home visiting
costs and funding allocation. Data
categories within the tool were chosen
to address these identified needs and fill
in gaps in existing research. To ensure
consistency in data collected across
three cohorts of respondents, HRSA is
not proposing to make updates to the
data collection instrument itself at this
time. However, in response to feedback
on burden, the estimated average
burden per response was increased from
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
24 to 40 hours, which includes burden
on both LIAs and state-level awardees.
In addition, awardees will have the
option for HRSA to aggregate their LIAlevel HV–BAT data, decreasing awardee
burden. HRSA values the comments
received regarding technical assistance,
such as challenges with the tool and the
utility of feedback received during the
first round of submissions. HRSA is in
the process of refining technical
assistance materials and processes to
better support awardees in response to
these comments and to decrease
awardee time spent on back-and-forth
regarding HV–BAT revisions.
Need and Proposed Use of the
Information: HRSA uses HV–BAT data
to collect comprehensive home visiting
cost data. Awardees submit aggregated
data from their individual LIAs, which
provides HRSA with information
needed to produce state and national
cost estimates and support procurement
activities and subrecipient monitoring.
Requiring data submission also allows
HRSA to ensure the tool is being
accurately and appropriately used.
Because the use of a standardized tool
of this kind is novel to the field of home
visiting, HRSA requires that states
submit data collected using HV–BAT to
HRSA for the purposes of quality
control reviews and accuracy checks.
Submission will allow HRSA to
estimate national-level costs for use in
conducting research and analysis of
home visiting costs, understanding cost
variation, and assessing how
comprehensive program cost data can
inform other policy priorities, such as
innovative financing strategies. HRSA is
seeking to revise burden estimates to
ensure accuracy and inform awardee
planning for this activity. In addition,
HRSA is translating the HV–BAT data
collection instrument into Spanish in
response to previous awardee feedback
and to increase accessibility for LIA
sites that primarily operate in Spanish.
Likely Respondents: One-third of
MIECHV Program awardees (n=19,
annually) that are states, jurisdictions,
and nonprofit organizations receiving
MIECHV funding to provide home
visiting services within states.
Burden Statement: Burden in this
context means the time expended by
persons to generate, maintain, retain,
disclose, or provide the information
requested. This includes the time
needed to review instructions; to
develop, acquire, install, and utilize
technology and systems for the purpose
of collecting, validating, and verifying
information, processing and
maintaining information, and disclosing
and providing information; to train
personnel and to be able to respond to
E:\FR\FM\01MRN1.SGM
01MRN1
12953
Federal Register / Vol. 88, No. 40 / Wednesday, March 1, 2023 / Notices
a collection of information; to search
data sources; to complete and review
the collection of information; and to
transmit or otherwise disclose the
information. The total annual burden
hours estimated for this ICR are
summarized in the table below.
TOTAL ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Form name
Total
responses
Average
burden per
response
(in hours)
Total
burden hours
Home Visiting Budget Assistance Tool ...............................
19
13
247
40
9,880
Total ..............................................................................
19
13
247
40
9,880
Maria G. Button,
Director, Executive Secretariat.
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Agency Information Collection
Activities: Proposed Collection: Public
Comment Request; Information
Collection Request Title: Biographical
Sketch Form for Use With Applications
to the Maternal and Child Health
Bureau Research Grants OMB No.
0906–Reinstatement
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services.
ACTION: Notice.
AGENCY:
In compliance with the
requirement for opportunity for public
comment on proposed data collection
projects of the Paperwork Reduction Act
of 1995, HRSA announces plans to
submit an Information Collection
Request (ICR), described below, to the
Office of Management and Budget
(OMB). Prior to submitting the ICR to
OMB, HRSA seeks comments from the
public regarding the burden estimate,
below, or any other aspect of the ICR.
DATES: Comments on this ICR should be
received no later than May 1, 2023.
ADDRESSES: Submit your comments to
paperwork@hrsa.gov or by mail to the
HRSA Information Collection Clearance
Officer, Room 14N136B, 5600 Fishers
Lane, Rockville, MD 20857.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the data collection plans and draft
instruments, email paperwork@hrsa.gov
or call Samantha Miller, the HRSA
Information Collection Clearance
Officer, at (301) 443–1984.
SUMMARY:
VerDate Sep<11>2014
18:10 Feb 28, 2023
When
submitting comments or requesting
information, please include the ICR title
for reference.
Information Collection Request Title:
Forms for Use with Applications to the
Maternal and Child Health Bureau
Research Grants, OMB No. 0906Reinstatement.
Abstract: HRSA is requesting
reinstatement of the Biographical Sketch
Form for use with applications to the
Maternal and Child Health Bureau
Research Grants (Biographical Sketch)
for HRSA’s SF424 Research and Related
(R&R) application package. These grants
are funded by a number of authorities
such as 42 U.S.C. 701(a)(2) (title V,
section 501(a)(2) of the Social Security
Act) and by 42 U.S.C. 280i-1(f) (title III,
section 399BB(f) of the Public Health
Service Act. The purpose of these grants
is to advance the health and well-being
of Maternal and Child Health
populations and children and
adolescents with autism spectrum
disorder by supporting innovative,
applied, and translational intervention
research studies on critical issues
affecting these populations.
Need and Proposed Use of the
Information: HRSA plans to use the
Biographical Sketch as a required
element of the SF424 R&R application
package. The applicants use the
Biographical Sketch form to summarize
the qualifications of each key personnel
on their proposed research team,
including education/training, positions
and honors, contributions to science,
and related experience. The grant
reviewers will use this information to
assess the capabilities of the research
team to carry out the planned research
project. The Biographical Sketch form
also collects demographic data (race,
ethnicity, and gender) for the Principal
Investigator and key program staff or, for
applicants that are uncomfortable
reporting this information, they can
mark their demographic information as
‘‘Not Reported/Unknown;’’ this will
SUPPLEMENTARY INFORMATION:
[FR Doc. 2023–04185 Filed 2–28–23; 8:45 am]
ddrumheller on DSK120RN23PROD with NOTICES
Number of
responses per
respondent
Jkt 259001
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
have no impact on funding decisions.
Collecting demographic information
allows HRSA to determine to what
extent individuals of different
backgrounds are participating. This
information, in addition to other
information including career stage,
geographic location of the institution,
and educational level assists HRSA in
ensuring that federal grant and
cooperative agreement awards are
reaching diverse populations.
HRSA is considering several changes
for the Biographical Sketch:
• Clarifying instructions: Provides the
applicant more information on what
should and should not be included on
the biographical sketch.
• Removal of Section D: Section D:
Related Experience has been removed.
• Removal of Section E: Section E:
Additional Information: Research
Support and/or Scholastic Performance
Awards has been removed.
• ‘‘Some Other Race’’ Category: At
the request of our applicants, this
category was added.
Likely Respondents: Respondents are
applicants to HRSA’s Maternal and
Child Health Bureau research programs.
Burden Statement: Burden includes
the time expended by persons to
generate, maintain, retain, disclose, or
provide the information requested. This
includes the time needed to review
instructions; to develop, acquire, install,
and utilize technology and systems for
the purpose of collecting, validating,
and verifying information, processing
and maintaining information, disclosing
and providing information. It also
accounts for time to train personnel,
respond to a collection of information,
search data sources, complete and
review the collection of information,
and transmit or otherwise disclose the
information. The total annual burden
hours estimated for this Information
Collection Request are summarized in
the table below.
Total Estimated Annualized Burden
Hours:
E:\FR\FM\01MRN1.SGM
01MRN1
]]>Agencies
[Federal Register Volume 88, Number 40 (Wednesday, March 1, 2023)]
[Notices]
[Pages 12951-12953]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-04185]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration
Agency Information Collection Activities: Submission to OMB for
Review and Approval; Public Comment Request; Maternal, Infant, and
Early Childhood Home Visiting Program Home Visiting Program Budget
Assistance Tool
AGENCY: Health Resources and Services Administration (HRSA), Department
of Health and Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: In compliance with the Paperwork Reduction Act of 1995, HRSA
submitted an Information Collection Request (ICR) to the Office of
[[Page 12952]]
Management and Budget (OMB) for review and approval. Comments submitted
during the first public review of this ICR will be provided to OMB. OMB
will accept further comments from the public during the review and
approval period. OMB may act on HRSA's ICR only after the 30-day
comment period for this notice has closed.
DATES: Comments on this ICR should be received no later than March 31,
2023.
ADDRESSES: Written comments and recommendations for the proposed
information collection should be sent within 30 days of publication of
this notice to www.reginfo.gov/public/do/PRAMain. Find this particular
information collection by selecting ``Currently under Review--Open for
Public Comments,'' or by using the search function.
FOR FURTHER INFORMATION CONTACT: To request more information on the
proposed project or to obtain a copy of the data collection plans and
draft instruments, email [email protected] or call Samantha Miller,
the acting HRSA Information Collection Clearance Officer, at 301-594-
4394.
SUPPLEMENTARY INFORMATION:
Information Collection Request Title: Maternal, Infant, and Early
Childhood Home Visiting (MIECHV) Program Home Visiting Budget
Assistance Tool (HV-BAT), OMB No. 0906-0025--Revision.
Abstract: HRSA is requesting an extension of approval and revision
to the burden estimates for the HV-BAT. The tool collects information
on standardized cost metrics from programs that deliver home visiting
services. Entities receiving MIECHV formula funds that are states,
jurisdictions, and nonprofit awardees are required to submit cost data
using the HV-BAT to HRSA once every 3 years to be reviewed for accuracy
and quality control and to collect data to estimate national program
costs.
The MIECHV Program, authorized by section 511 of the Social
Security Act, 42 U.S.C. 711, and administered by HRSA in partnership
with the Administration for Children and Families, supports voluntary,
evidence-based home visiting services during pregnancy and for parents
with young children up to kindergarten entry. States, tribal entities,
and certain nonprofit organizations are eligible to receive funding
from the MIECHV Program and have the flexibility to tailor the program
to serve the specific needs of their communities. Funding recipients
may subaward grant funds to local implementing agencies (LIAs) to
provide services to eligible families in at-risk communities. HRSA is
making the following changes to the HV-BAT:
Updating the burden estimate for completing the HV-BAT
based on recently gathered information. The burden estimate reflects
both awardee and LIA staff hours to complete an HV-BAT. HRSA expects
the majority of awardees will be submitting data from multiple LIAs,
and some LIAs may submit multiple HV-BATs to account for each model
implemented at their site.
Translating the HV-BAT data collection instrument into
Spanish to expand accessibility.
A 60-day notice was published in the Federal Register on November
8, 2022, 87 FR 67481-82. HRSA received five responses to the request
for public comment. Two commentors are current MIECHV awardees, one is
a home visiting model developer, one is a national membership
organization representing MIECHV awardees, and one is a consultancy
group directing a national initiative relating to home visiting.
Commentors posed questions about the utility of HV-BAT data (e.g.,
relevance of data collected from the prior year, lack of data context
collected through the tool, how HRSA will account for variation in
local labor markets) and of the specific data items collected (e.g.,
necessity of collecting rural and frontier visit data, MIECHV funding
percentages, and combined salary and fringe data). In addition,
commentors provided recommendations for updating burden estimates and
improving HRSA's technical assistance and feedback (e.g., providing
support for estimating in-kind costs and additional suggestions for
review and feedback from HRSA).
HRSA views HV-BAT as an important tool for collecting standardized
cost information across awardees, understanding the comprehensive costs
of home visiting, and informing program planning and policy. During HV-
BAT tool development, HRSA reviewed available cost measurement reports,
tested the tool with awardees during the pilot and feasibility studies,
and assessed the types of data that would be critical for understanding
home visiting costs and funding allocation. Data categories within the
tool were chosen to address these identified needs and fill in gaps in
existing research. To ensure consistency in data collected across three
cohorts of respondents, HRSA is not proposing to make updates to the
data collection instrument itself at this time. However, in response to
feedback on burden, the estimated average burden per response was
increased from 24 to 40 hours, which includes burden on both LIAs and
state-level awardees. In addition, awardees will have the option for
HRSA to aggregate their LIA-level HV-BAT data, decreasing awardee
burden. HRSA values the comments received regarding technical
assistance, such as challenges with the tool and the utility of
feedback received during the first round of submissions. HRSA is in the
process of refining technical assistance materials and processes to
better support awardees in response to these comments and to decrease
awardee time spent on back-and-forth regarding HV-BAT revisions.
Need and Proposed Use of the Information: HRSA uses HV-BAT data to
collect comprehensive home visiting cost data. Awardees submit
aggregated data from their individual LIAs, which provides HRSA with
information needed to produce state and national cost estimates and
support procurement activities and subrecipient monitoring. Requiring
data submission also allows HRSA to ensure the tool is being accurately
and appropriately used. Because the use of a standardized tool of this
kind is novel to the field of home visiting, HRSA requires that states
submit data collected using HV-BAT to HRSA for the purposes of quality
control reviews and accuracy checks. Submission will allow HRSA to
estimate national-level costs for use in conducting research and
analysis of home visiting costs, understanding cost variation, and
assessing how comprehensive program cost data can inform other policy
priorities, such as innovative financing strategies. HRSA is seeking to
revise burden estimates to ensure accuracy and inform awardee planning
for this activity. In addition, HRSA is translating the HV-BAT data
collection instrument into Spanish in response to previous awardee
feedback and to increase accessibility for LIA sites that primarily
operate in Spanish.
Likely Respondents: One-third of MIECHV Program awardees (n=19,
annually) that are states, jurisdictions, and nonprofit organizations
receiving MIECHV funding to provide home visiting services within
states.
Burden Statement: Burden in this context means the time expended by
persons to generate, maintain, retain, disclose, or provide the
information requested. This includes the time needed to review
instructions; to develop, acquire, install, and utilize technology and
systems for the purpose of collecting, validating, and verifying
information, processing and maintaining information, and disclosing and
providing information; to train personnel and to be able to respond to
[[Page 12953]]
a collection of information; to search data sources; to complete and
review the collection of information; and to transmit or otherwise
disclose the information. The total annual burden hours estimated for
this ICR are summarized in the table below.
Total Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Form name Number of responses per Total per response Total burden
respondents respondent responses (in hours) hours
----------------------------------------------------------------------------------------------------------------
Home Visiting Budget Assistance 19 13 247 40 9,880
Tool...........................
-------------------------------------------------------------------------------
Total....................... 19 13 247 40 9,880
----------------------------------------------------------------------------------------------------------------
Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2023-04185 Filed 2-28-23; 8:45 am]
BILLING CODE 4165-15-P
